While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

NanoViricides announced that the FDA has granted both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) designations to its lead candidate NV-387 for the treatment of measles. These designations qualify the company for incentives such as tax credits and market exclusivity, and make NV-387 eligible for a Priority Review Voucher (PRV) upon future marketing approval, a benefit recently valued at $195 million in a comparable transaction. The company is currently developing a Phase II clinical trial protocol to evaluate NV-387 as a measles treatment, aiming to address rising cases in the U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.